September 14, 2009 - Portland, OR - Artielle ImmunoTherapeutics, a clinical stage biopharmaceutical company announced today the presentation of "Results of a Phase 1 safety study of RTL1000, a recombinant T-Cell receptor ligand specific for an immunodominant MOG peptide, in multiple sclerosis." The results were presented yesterday by one of Artielle's founding scientists, Arthur Vandenbark, PhD., at the Congress of the European Federation of Neurological Societies in Florence, Italy. Full Text
March 14, 2007 - Portland, Ore. - Artielle ImmunoTherapeutics, Inc. today announced that the Company has initiated a Phase I clinical trial to evaluate its novel drug candidate, RTL1000, for the treatment of multiple sclerosis (MS). RTL1000 is a novel protein drug with a highly-selective mechanism of action that targets pathogenic T-cells responsible for triggering and sustaining MS. Full Text
June 28, 2004 - Portland, Ore. - Virogenomics, Inc. announced today that it has spun-off its autoimmune disease technology into a new company, Artielle ImmunoTherapeutics, Inc. (Artielle), and raised $11 million in venture capital funding for Artielle. Full Text
